We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EBF:NYSEEnnis, Inc. Analysis

Data as of 2026-05-19 - not real-time

$20.39

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Ennis, Inc. is trading just above its short‑term moving average while remaining below the longer‑term average, signaling a neutral price bias. The relative strength index sits in the mid‑range, indicating neither overbought nor oversold conditions. However, the MACD has turned bearish, and declining volume suggests waning short‑term momentum. The stock’s beta is low, pointing to reduced sensitivity to overall market swings, yet the recent 30‑day volatility is elevated, reflecting price swings that could surprise investors. Fundamentally, the price‑to‑earnings multiple is well under the industry average, and the dividend yield is attractive with a payout ratio that appears sustainable. A discounted cash‑flow model implies a notable upside potential, reinforcing the undervalued narrative.
Recent earnings matched the prior year’s results, providing a measure of earnings stability. Strong operating margins and solid free cash flow underpin the ability to maintain the dividend. The balance sheet shows modest debt and ample cash, supporting financial flexibility. While technical indicators are mixed, the fundamental story—steady profitability, generous dividend, and upside valuation—makes the stock appealing for patient investors. The decreasing volume trend and neutral technical stance suggest caution in the very short term, but the longer‑term outlook remains positive.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • bearish MACD and decreasing volume
  • mid‑range RSI indicating no clear momentum
  • attractive dividend yield for income‑focused investors

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • DCF‑derived upside potential
  • low beta and defensive dividend profile
  • PE well below industry peers suggesting value

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • consistent profitability and solid free cash flow
  • sustainable dividend with reasonable payout ratio
  • stable balance sheet and modest debt levels

Key Metrics & Analysis

Financial Health

Revenue Growth4.00%
Profit Margin10.86%
P/E Ratio12.3
ROE13.96%
ROA9.11%
Debt/Equity2.98
P/B Ratio1.7
Op. Cash Flow$52.7M
Free Cash Flow$25.3M
Industry P/E29.5

Technical Analysis

TrendNeutral
RSI46.3
Support$19.70
Resistance$21.14
MA 20$20.45
MA 50$20.99
MA 200$19.02
MACDBearish
VolumeDecreasing
Fear & Greed Index89.61

Valuation

Fair Value$16.44
Target Price$24.00
Upside/Downside17.70%
GradeUndervalued
TypeValue
Dividend Yield4.90%

Risk Assessment

Beta0.50
Volatility34.31%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.